The acquisition was funded through cash on hand.
The assets were acquired from a Dutch subsidiary of Merck by ANI Pharmaceuticals C.V., a Netherlands based wholly owned indirect subsidiary of ANI.
ANI Pharmaceuticals president and CEO Arthur Przybyl said: "Having now closed the acquisition of the corticotrophin NDAs, we look forward to advancing our re-commercialization plan."